Data Presented at ASCO Demonstrate Trilaciclib Helps Protect Against Severe Neutropenia, Severe Anemia, and Severe Thrombocytopenia When Given to Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients Prior to Chemotherapy
June 02, 2022 11:00 ET
|
G1 Therapeutics
- Patients Receiving Trilaciclib Experienced a Lower Incidence of Single-Lineage and Multilineage Chemotherapy-Induced Myelosuppressive Events Compared with Patients Receiving Placebo - - Total...
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2022 16:45 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
G1 Therapeutics Named 2022 Life Sciences Public Company of the Year by Triangle Business Journal
May 20, 2022 10:30 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., May 20, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it received Triangle Business Journal's...
G1 Therapeutics to Participate in the H.C. Wainwright & Co. Global Investment Conference
May 18, 2022 10:15 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., May 18, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1’s Chief Executive...
G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights
May 04, 2022 06:30 ET
|
G1 Therapeutics
- Achieved $6.9 Million in Total Revenue in the First Quarter of 2022, Including $5.5 Million in Net Revenue from Sales of COSELA™ (trilaciclib) - - Fully Deployed G1’s COSELA Sales Team as of...
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2022 17:30 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., May 02, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
G1 Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 4, 2022
April 21, 2022 08:30 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., April 21, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a...
G1 Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
April 06, 2022 11:30 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., April 06, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey and Raj Malik, M.D., G1’s...
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 01, 2022 16:15 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., April 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
New Real-World Data Show Potential of Trilaciclib to Reduce the Substantial Burden of Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Treated with Chemotherapy
March 31, 2022 16:05 ET
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., March 31, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced results of a retrospective, observational...